Randomised, Double-Blind, Placebo-Controlled Study to Investigate GNbAC1 in Patients With Onset of Type 1 Diabetes Within 4 Years

Trial Profile

Randomised, Double-Blind, Placebo-Controlled Study to Investigate GNbAC1 in Patients With Onset of Type 1 Diabetes Within 4 Years

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2017

At a glance

  • Drugs GNbAC1 (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions
  • Acronyms RAINBOW-T1D
  • Sponsors GeNeuro Australia
  • Most Recent Events

    • 04 Dec 2017 Planned End Date changed from 1 Sep 2018 to 1 Mar 2019.
    • 19 Jun 2017 According to a GeNeuro media release, the first patient has been treated in this trial. Richard W. Simpson is a national investigator of this study. Last patient enrolment is expected by the end of 2017 and preliminary results are expected during the third quarter 2018.
    • 09 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top